LeMaitre Vascular Reports Strong Q4 Growth and Boosts Shareholder Returns

Key Facts

1LeMaitre Vascular achieved 16% YoY sales growth in Q4 and FY 2025.

2The international rollout of Artegraft exceeded expectations, with projected sales of $10M in 2026.

3The company increased its dividend by 25% and authorized a $100M share repurchase program.

4The company maintains a robust net cash position of $190M.

LeMaitre Vascular (LMAT) reported a robust performance for the fourth quarter and full year 2025, with sales increasing by 16% year-over-year. The growth was largely driven by the successful international rollout of its Artegraft product line, which is projected to reach $10 million in sales by 2026. In a move to reward investors, the company announced a 25% increase in its quarterly dividend and authorized a new $100 million share repurchase program. Financial stability remains a core strength, as the firm maintains a net cash position of $190 million with zero debt on its balance sheet. Management highlighted that margin expansion and strong operational performance across its vascular surgery portfolio underpinned these results. Analysts view the combination of double-digit growth and increased capital returns as a positive signal for the stock's future trajectory.